The seminar is part of the Industry Insight Seminar Series (IISS), run by the Medical Sciences Division at the University of Oxford, and will be held virtually on Tuesday 7 September 2021 at 12.00 noon.

Speaker: Dr Katharina Duerr, Director for Protein Biochemistry and Structural Biology, OMass

OMass is an Oxford University spin-out that is harnessing high-resolution native mass spectrometry and other biophysical technologies to drive drug discovery in high definition for immunology and genetic disease.

Abstract: OMass is an Oxford University spin-out backed by Syncona Ltd and Oxford Sciences Innovation that is harnessing high-resolution native mass spectrometry and other biophysical technologies to drive drug discovery in high definition for immunology and genetic disease. The company uses its suite of proprietary technologies based on high-resolution mass spectrometry to study intact protein assemblies. The technology enables detection of drug leads that not only bind to the target complex, but also exert a functional effect through modulation of complex formation, with both effects, binding and function, being measured by a change in mass. These methods are being applied to drug discovery for a variety of complex targets, focusing on membrane receptors.

The Industry Insight Seminars provide a great opportunity to:

• Increase awareness of commercial translation
• Form connections between academics and industry
• Network with potential collaborators

These seminars are suitable for all scientists with some knowledge or interest in each topic area, from PhD students to PIs along with biotech, SMEs and Pharma companies.

If you would like a one-to-one meeting with Dr Katharina Duerr, please contact Sheena Lee, Business Partnership and Team Planning Manager, Medical Sciences Division